The clinical manifestation, survival outcome and predictive prognostic factors of 137 patients with primary gastrointestinal lymphoma (PGIL)

Shi, Zhan; Ding, Hao; Shen, Qian; Lü, Xin; Chen, Jia Yan; Chen, Xi; Tang, Xi

doi:10.1097/md.0000000000009583

Cited by 13 publications

(9 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Our study also indicates that small intestinal lesions (mainly terminal ileum lesions) are more common in MCL cases. Several studies have reported the features of GI MLs (such as incidence rate, subtype frequency, localization, and prognosis) (19)(20)(21)(22). They revealed that the prognoses of ML cases involving overlapping lesions and advanced stages were significantly poorer than those of ML cases involving single lesions and early stages (9,14,23).…”

Section: Discussionmentioning

confidence: 99%

Need to Inspect the Total Gastrointestinal Tract of Patients With Malignant Lymphomas

Maruyama

Yamasaki

Miyashita

et al. 2021

In Vivo

View full text Add to dashboard Cite

Background/Aim: Malignant lymphoma (ML) cases with overlapping gastrointestinal (GI) lesions are often encountered. We aimed to elucidate the importance of examining the GI tract in patients with ML and assess the overlap rate. Patients and Methods: We analysed 190 patients diagnosed with GI MLs. We compared the overlap rates among the different histopathological types. Results: Twenty-five (13.2%) patients had overlapping GI lesions in more than two segments. The overlap rates were 100% in mantle cell lymphomas (MCL), 27.6% in follicular lymphomas (FL), and 16.3% in diffuse large B-cell lymphomas (DLBCL). MCL, FL, and DLBCL cases showed significantly higher overlap rates than mucosa-associated lymphoid tissue lymphoma cases (p<0.01). About 64.0% of cases of ML with overlapping lesions involved the small intestine. Conclusion: In GI ML cases, it is ideal to examine the entire GI tract by esophagogastroduodenoscopy, colonoscopy, and capsule endoscopy and/or balloon-assisted endoscopy, especially in MCL, FL, and DLBCL. Malignant lymphomas (MLs) are classified as either Hodgkin's or non-Hodgkin's lymphomas. Non-Hodgkin MLs are sub-divided into nodal and extranodal lymphomas. Although primary gastrointestinal (GI) MLs comprise only 2785 This article is freely accessible online.

show abstract

Section: Discussionmentioning

confidence: 99%

Need to Inspect the Total Gastrointestinal Tract of Patients With Malignant Lymphomas

Maruyama

Yamasaki

Miyashita

et al. 2021

In Vivo

View full text Add to dashboard Cite

show abstract

“…A retrospective multicenter clinical study of 299 B-cell lymphoma cases revealed IPI ≥2 to be an independent prognostic factor for worse OS ( 32 ). However, Shi et al study of 137 patients found that there was no apparent prognostic significant correlation between IPI and survival ( 33 ). Lugano staging system was also used to modify the IPI for primary GI NHL ( 34 , 35 ).…”

Section: Discussionmentioning

confidence: 99%

Nomogram for Predicting the Overall Survival of Adult Patients With Primary Gastrointestinal Diffuse Large B Cell Lymphoma: A SEER- Based Study

Wang

Zhou

et al. 2020

Front. Oncol.

View full text Add to dashboard Cite

Background: The aim of this study was to establish a precise prognostic model, based on significant clinical parameters, for predicting the overall survival (OS) of adult patients with primary gastrointestinal diffuse large B cell lymphoma (GI DLBCL). Materials and Methods: The data of 7,121 GI DLBCL patients, diagnosed between 1997 and 2015, were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. These patients were randomly divided into two sequential cohorts: training (n = 5,697) set and validation (n = 1,424) set. ROC methodology and calibration curves were explicitly used to evaluate the predictive performance of nomogram. Results: The median OS in the training cohort was 76 months (1-239 months), and 3, 5, and 10-year OS rates were 60.3, 53.9, and 39.5%, respectively. Age at diagnosis, Ann Arbor stage, and marital status were important clinical predictors of OS. These characteristics were used to build a nomogram. The AUC of the nomogram for predicting 3, 5, and 10-year OS were 0.669, 0.692, and 0.740, respectively. All RUC and calibration curves revealed good accuracy in predicting prognosis of GI DLBCL. Conclusion: In summary, the established nomogram was validated to predict OS for adult patients with GI DLBCL. This predictive model could help clinicians identify high-risk patients to improve their prognosis.

show abstract

“…In this study, age was not found to have significant relation in responders and nonresponders which is in contradiction to published facts that age is considered as a negative predictor of response. [14] BMI is considered as a better predictor of response and overall survival (OS) in patients with lymphoma. [15] Our data did not show any impact of BMI in responders and nonresponders.…”

Section: Discussionmentioning

confidence: 99%

“…These observations are in contradiction to published findings revealing the poor impact of bulky disease, staging, and extranodal involvement on PFS. [14] HL responders were found to be significantly younger with a higher decline in BMI as compared to NHL responders. This could be secondary to wider range of BMI at baseline in HL patients.…”

Section: Discussionmentioning

confidence: 99%

Predictors of metabolic response in propensity-matched lymphoma patients on interim 18F-fluorodeoxyglucose positron-emission tomography/computed tomography using standardized imaging and reporting protocol: Do we really have one?

Fatima

Zaman

et al. 2019

World J Nucl Med

View full text Add to dashboard Cite

The purpose of this prospective study was to determine metabolic response predictor(s) in propensity-matched patients having lymphomas who had baseline and interim 18 fluorodeoxyglucose (FDG) positron-emission tomography/computed tomography (PET/CT) using strict standardized imaging and reporting protocols. This prospective study was conducted at PET/CT section of a JCI-accredited healthcare facility from April 2017 to February 2018. Patients with baseline and interim 18 FDG PET/CT scans using standardized protocol were selected. Interim scans were performed not earlier than 2 nd or later than 4 th chemotherapy. During the study period, 97 of 112 consecutive patients with lymphomas (Hodgkin-HL: 32/97 and Non-Hodgkin-NHL: 65/97) were included in the study. Mean age of cohort was 45 ± 19 years (71% male and 29% female) having a mean body mass index (BMI) of 25.57 ± 5.54 Kg/m 2 having Stage I (21%), Stage II (18%), Stage III (16%), and Stage IV (45%) disease. Bulky disease was found in 14% and 18 FDG-avid marrow deposits in 33%. Standardized PET/CT imaging protocol as per EANM guidelines was strictly adopted for baseline and interim studies. %Δ changes in fasting blood sugar, 18 FDG dose, uptake time, and liver SUV mean were 3.96%, 2.83%, 2.49%, and 12.15%, respectively. Based on Deauville's scoring, cohort was divided into responders having Score 1–3 (49/97) and nonresponders having Score 4–5 (48/97). The demographic analysis found no significant difference between responders and nonresponders for age, gender, BMI, staging, bulky disease or marrow involvement, and study protocol. No significant coefficient or odd ratios were found on multivariate analysis for age, gender, maximum standardized uptake value (SUV max ), size, BMI, NHL, and advance disease (Stage III and IV) in both groups (χ 2 : 5.12; receiver operating characteristic [95% confidence interval]: 0.616 [0.51–0.713]; P =0.528). Among responders, baseline SUV max and tumor size had a direct correlation with a metabolic response on iPET, more pronounced in NHL than HL groups (SUV max : 13.4 vs. 19.5 and size: 52 vs. 87 mm; P < 0.0001). We conclude that no significant predictor was found for response in propensity-matched patients with lymphomas (both HL and NHL) who had baseline and interim PET/CTs acquired with a standardized protocol. However, NHL responders were found to have higher baseline median SUV max and larger lesion size as compared to HL responders. Although, these data are not in concordance with published findings but need to be validated with larger studies using standardized imaging and reporting protocols in propensity-matched patients with lymphomas.

show abstract

The clinical manifestation, survival outcome and predictive prognostic factors of 137 patients with primary gastrointestinal lymphoma (PGIL)

Cited by 13 publications

References 33 publications

Need to Inspect the Total Gastrointestinal Tract of Patients With Malignant Lymphomas

Need to Inspect the Total Gastrointestinal Tract of Patients With Malignant Lymphomas

Nomogram for Predicting the Overall Survival of Adult Patients With Primary Gastrointestinal Diffuse Large B Cell Lymphoma: A SEER- Based Study

Predictors of metabolic response in propensity-matched lymphoma patients on interim 18F-fluorodeoxyglucose positron-emission tomography/computed tomography using standardized imaging and reporting protocol: Do we really have one?

Contact Info

Product

Resources

About